# A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Health Subject

> **NCT04041544** · PHASE1 · UNKNOWN · sponsor: **SinoMab BioScience Ltd** · enrollment: 80 (estimated)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** SN1011
- **DRUG:** SN1011 placebo

## Key facts

- **NCT ID:** NCT04041544
- **Lead sponsor:** SinoMab BioScience Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-27
- **Primary completion:** 2020-07
- **Final completion:** 2020-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2019-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04041544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04041544, "A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Health Subject". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04041544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*